ArticleTranslational breast cancer research : a journal focusing on translational research in breast cancer2026
The preliminary study on the effect of PSEN1 on the proliferation and invasion of breast cancer cells.
Article in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Erratum: The preliminary study on the effect of PSEN1 on the proliferation and invasion of breast cancer cells.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the most common form of cancer among women, and PSEN1 dysfunction is a primary contributor to the pathogenesis of Alzheimer's disease. However, the involvement of PSEN1 in breast cancer remains unclear. This study was conducted to explore the function and related mechanisms of PSEN1 in breast cancer cells. Methods: The correlation between two genes was determined utilizing the R2 platform, and the association between gene expression and prognosis was analyzed employing the Kaplan-Meier plotter. The expression of PSEN1 in breast cancer was assessed by in immunofluorescence. The Transwell assay was employed to detect the migration and invasion capabilities of cells. Colony formation and EdU staining were employed to evaluate the effects of PSEN1 on breast cancer cell proliferation. Results: We observed a positive correlation between the expression of PSEN1 and the prognosis of breast cancer patients. After manipulated the expression of PSEN1 in breast cancer cell lines Sum159 and BT549, we found that PSEN1 could inhibit cell proliferation and growth in breast cancer through colony formation assays and EdU staining. Meanwhile, we revealed that interference with the cell cycle by PSEN1 was associated with cyclin-dependent kinases (CDKs) and cyclin-dependent kinase inhibitors (CKIs) in breast cancer samples. Furthermore, we observed that an increase in PSEN1 expression inhibited the invasive capabilities of breast cancer cells, while a decrease in PSEN1 expression enhanced invasion in both Sum159 and BT549 cell lines. Lastly, we discovered a negative correlation between PSEN1 and epithelial-to-mesenchymal transition (EMT) transcription factors as well as markers in breast cancer patients. Conclusions: Our study demonstrates that PSEN1 inhibits the invasion and proliferation of breast cancer cells, suggesting that PSEN1 could potentially serve as a prognostic biomarker and a novel therapeutic target for patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.